← Back to Screener
GeoVax Labs, Inc. New (GOVX)
Price$1.17
Favorite Metrics
Price vs S&P 500 (26W)-99.81%
Price vs S&P 500 (4W)-25.14%
Market Capitalization$3.59M
All Metrics
Book Value / Share (Quarterly)$2.21
P/TBV (Annual)3.90x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)212.58%
Cash Flow / Share (Quarterly)$-13.17
Price vs S&P 500 (YTD)-75.17%
Gross Margin (TTM)-31.76%
Net Profit Margin (TTM)-403.80%
EPS (TTM)$-30.28
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-30.28
Revenue Growth (5Y)6.42%
EPS (Annual)$-22.40
ROI (Annual)-561.15%
Gross Margin (Annual)25.00%
Net Profit Margin (5Y Avg)-4735.50%
Cash / Share (Quarterly)$1.78
ROA (Last FY)-338.46%
Revenue Growth TTM (YoY)-37.06%
EBITD / Share (TTM)$-23.71
ROE (5Y Avg)-397.04%
Operating Margin (TTM)-407.34%
Cash Flow / Share (Annual)$-13.17
P/B Ratio0.94x
P/B Ratio (Quarterly)1.34x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)0.08x
Net Interest Coverage (TTM)-19.93x
ROA (TTM)-293.47%
EPS Incl Extra (Annual)$-22.40
Current Ratio (Annual)2.74x
Quick Ratio (Quarterly)1.59x
3-Month Avg Trading Volume0.14M
52-Week Price Return-94.50%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.34
P/S Ratio (Annual)1.44x
Asset Turnover (Annual)0.39x
52-Week High$34.75
Operating Margin (5Y Avg)-4738.15%
EPS Excl Extra (Annual)$-22.40
CapEx CAGR (5Y)-29.34%
Tangible BV CAGR (5Y)-20.70%
26-Week Price Return-91.07%
Quick Ratio (Annual)1.59x
13-Week Price Return-56.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.74x
Enterprise Value$0.501
Revenue / Share Growth (5Y)-33.36%
Asset Turnover (TTM)0.69x
Book Value / Share Growth (5Y)-43.21%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)5.36x
Pretax Margin (Annual)-862.33%
Cash / Share (Annual)$1.78
3-Month Return Std Dev101.88%
Gross Margin (5Y Avg)-920.72%
Net Income / Employee (TTM)$-1
ROE (Last FY)-561.15%
Net Interest Coverage (Annual)-2781.44x
EPS Basic Excl Extra (Annual)$-22.40
P/FCF (TTM)8.78x
Receivables Turnover (TTM)7.55x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-30.28
Receivables Turnover (Annual)7.55x
ROI (TTM)-441.40%
P/S Ratio (TTM)0.58x
Pretax Margin (5Y Avg)-4735.50%
Revenue / Share (Annual)$2.60
Tangible BV / Share (Annual)$1.01
Price vs S&P 500 (52W)-129.60%
Year-to-Date Return-71.03%
5-Day Price Return-3.13%
EPS Normalized (Annual)$-22.40
ROA (5Y Avg)-225.35%
Net Profit Margin (Annual)-862.33%
Month-to-Date Return-10.14%
Cash Flow / Share (TTM)$-0.90
EBITD / Share (Annual)$-22.51
Operating Margin (Annual)-869.33%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-397.04%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-30.28
P/TBV (Quarterly)3.90x
P/B Ratio (Annual)1.34x
Inventory Turnover (TTM)5.82x
Pretax Margin (TTM)-403.80%
Book Value / Share (Annual)$2.21
Price vs S&P 500 (13W)-59.51%
Beta3.59x
P/FCF (Annual)22.42x
Revenue / Share (TTM)$1.44
ROE (TTM)-441.40%
52-Week Low$1.14
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GOVXGeoVax Labs, Inc. New | 0.58x | -37.06% | -31.76% | — | $1.17 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine in human trials, complemented by candidates targeting Monkeypox, hemorrhagic fevers, Zika, and head and neck cancer. The company's approach combines preventive vaccines and gene-directed immunotherapies across a diversified pipeline.